nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—Bromocriptine—DRD4—conduct disorder	0.0428	0.516	CrCbGaD
Dihydroergotamine—HTR6—Serotonin receptors—HTR2A—conduct disorder	0.0363	0.0396	CbGpPWpGaD
Dihydroergotamine—HTR1D—Serotonin receptors—HTR2A—conduct disorder	0.0361	0.0393	CbGpPWpGaD
Dihydroergotamine—HTR1B—Serotonin receptors—HTR2A—conduct disorder	0.0353	0.0385	CbGpPWpGaD
Dihydroergotamine—HTR2B—Serotonin receptors—HTR2A—conduct disorder	0.0332	0.0362	CbGpPWpGaD
Dihydroergotamine—HTR1A—Serotonin receptors—HTR2A—conduct disorder	0.0269	0.0293	CbGpPWpGaD
Dihydroergotamine—HTR6—Monoamine GPCRs—DRD4—conduct disorder	0.0248	0.027	CbGpPWpGaD
Dihydroergotamine—HTR1D—Monoamine GPCRs—DRD4—conduct disorder	0.0246	0.0268	CbGpPWpGaD
Dihydroergotamine—HTR1B—Monoamine GPCRs—DRD4—conduct disorder	0.0241	0.0263	CbGpPWpGaD
Dihydroergotamine—HTR2B—Monoamine GPCRs—DRD4—conduct disorder	0.0226	0.0247	CbGpPWpGaD
Dihydroergotamine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—conduct disorder	0.022	0.024	CbGpPWpGaD
Dihydroergotamine—HTR6—Amine ligand-binding receptors—DRD4—conduct disorder	0.0208	0.0227	CbGpPWpGaD
Dihydroergotamine—HTR1D—Amine ligand-binding receptors—DRD4—conduct disorder	0.0207	0.0226	CbGpPWpGaD
Dihydroergotamine—Ergotamine—HTR2A—conduct disorder	0.0205	0.247	CrCbGaD
Dihydroergotamine—HTR1B—Amine ligand-binding receptors—DRD4—conduct disorder	0.0203	0.0221	CbGpPWpGaD
Dihydroergotamine—Bromocriptine—HTR2A—conduct disorder	0.0197	0.238	CrCbGaD
Dihydroergotamine—HTR2B—Amine ligand-binding receptors—DRD4—conduct disorder	0.019	0.0207	CbGpPWpGaD
Dihydroergotamine—HTR1A—Monoamine GPCRs—DRD4—conduct disorder	0.0184	0.02	CbGpPWpGaD
Dihydroergotamine—HTR6—Monoamine GPCRs—HTR2A—conduct disorder	0.0162	0.0176	CbGpPWpGaD
Dihydroergotamine—HTR1D—Monoamine GPCRs—HTR2A—conduct disorder	0.0161	0.0175	CbGpPWpGaD
Dihydroergotamine—HTR1B—Monoamine GPCRs—HTR2A—conduct disorder	0.0157	0.0171	CbGpPWpGaD
Dihydroergotamine—HTR1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.0154	0.0168	CbGpPWpGaD
Dihydroergotamine—HTR6—G alpha (s) signalling events—CGA—conduct disorder	0.0154	0.0167	CbGpPWpGaD
Dihydroergotamine—HTR2B—Monoamine GPCRs—HTR2A—conduct disorder	0.0148	0.0161	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Monoamine GPCRs—DRD4—conduct disorder	0.0144	0.0157	CbGpPWpGaD
Dihydroergotamine—HTR6—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0136	0.0148	CbGpPWpGaD
Dihydroergotamine—HTR1D—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0135	0.0147	CbGpPWpGaD
Dihydroergotamine—HTR1B—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0132	0.0144	CbGpPWpGaD
Dihydroergotamine—HTR2B—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0124	0.0135	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Amine ligand-binding receptors—DRD4—conduct disorder	0.0121	0.0132	CbGpPWpGaD
Dihydroergotamine—HTR1A—Monoamine GPCRs—HTR2A—conduct disorder	0.012	0.0131	CbGpPWpGaD
Dihydroergotamine—HTR1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0101	0.011	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Monoamine GPCRs—HTR2A—conduct disorder	0.00941	0.0103	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.00804	0.00877	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00791	0.00863	CbGpPWpGaD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00732	0.00798	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00726	0.00792	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00711	0.00776	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00668	0.00729	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00563	0.00614	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—CGA—conduct disorder	0.00557	0.00608	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—CGA—conduct disorder	0.00553	0.00603	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00542	0.00591	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—CGA—conduct disorder	0.00542	0.00591	CbGpPWpGaD
Dihydroergotamine—HTR1D—G alpha (i) signalling events—DRD4—conduct disorder	0.00512	0.00558	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—CGA—conduct disorder	0.00509	0.00555	CbGpPWpGaD
Dihydroergotamine—HTR1B—G alpha (i) signalling events—DRD4—conduct disorder	0.00501	0.00546	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00478	0.00522	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00475	0.00518	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00465	0.00507	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00437	0.00476	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00426	0.00464	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00424	0.00462	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—CGA—conduct disorder	0.00413	0.0045	CbGpPWpGaD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0041	0.00447	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00407	0.00444	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00398	0.00434	CbGpPWpGaD
Dihydroergotamine—HTR1A—G alpha (i) signalling events—DRD4—conduct disorder	0.00382	0.00416	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00374	0.00408	CbGpPWpGaD
Dihydroergotamine—HTR2B—G alpha (q) signalling events—HTR2A—conduct disorder	0.00369	0.00402	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00354	0.00386	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00346	0.00377	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.0033	0.0036	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—CGA—conduct disorder	0.00324	0.00354	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—CGA—conduct disorder	0.00315	0.00344	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—CGA—conduct disorder	0.00313	0.00341	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00312	0.0034	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—DRD4—conduct disorder	0.00312	0.0034	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0031	0.00338	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—DRD4—conduct disorder	0.0031	0.00338	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—CGA—conduct disorder	0.00306	0.00334	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00303	0.00331	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00303	0.00331	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—DRD4—conduct disorder	0.00303	0.00331	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—DRD4—conduct disorder	0.003	0.00327	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—CGA—conduct disorder	0.00288	0.00314	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CGA—conduct disorder	0.00286	0.00312	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00285	0.00311	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—DRD4—conduct disorder	0.00285	0.00311	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CGA—conduct disorder	0.00284	0.0031	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00278	0.00304	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CGA—conduct disorder	0.00278	0.00303	CbGpPWpGaD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00267	0.00292	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00265	0.00289	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CGA—conduct disorder	0.00261	0.00285	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.0026	0.00283	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00247	0.0027	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00244	0.00266	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00238	0.0026	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CGA—conduct disorder	0.00233	0.00254	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00231	0.00252	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—DRD4—conduct disorder	0.00231	0.00252	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CGA—conduct disorder	0.00212	0.00231	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—HTR2A—conduct disorder	0.00204	0.00222	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—HTR2A—conduct disorder	0.00202	0.0022	CbGpPWpGaD
Dihydroergotamine—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.00198	0.00216	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00198	0.00216	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—HTR2A—conduct disorder	0.00198	0.00216	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—HTR2A—conduct disorder	0.00186	0.00203	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CGA—conduct disorder	0.00183	0.002	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00183	0.002	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00182	0.00198	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—DRD4—conduct disorder	0.00182	0.00198	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—DRD4—conduct disorder	0.00176	0.00192	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—DRD4—conduct disorder	0.00175	0.00191	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—DRD4—conduct disorder	0.00171	0.00187	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CGA—conduct disorder	0.00169	0.00184	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CGA—conduct disorder	0.00168	0.00183	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CGA—conduct disorder	0.00166	0.00181	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CGA—conduct disorder	0.00164	0.00179	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00163	0.00178	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—DRD4—conduct disorder	0.00161	0.00176	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—DRD4—conduct disorder	0.0016	0.00175	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—DRD4—conduct disorder	0.00159	0.00173	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—DRD4—conduct disorder	0.00156	0.0017	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00156	0.0017	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CGA—conduct disorder	0.00154	0.00168	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—HTR2A—conduct disorder	0.00151	0.00164	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—DRD4—conduct disorder	0.00146	0.00159	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—WASF1—conduct disorder	0.00135	0.00148	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—WASF1—conduct disorder	0.00134	0.00147	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—COMT—conduct disorder	0.00132	0.00144	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—WASF1—conduct disorder	0.00132	0.00144	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.00131	0.00143	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—DRD4—conduct disorder	0.00131	0.00142	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.0013	0.00142	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CGA—conduct disorder	0.00125	0.00136	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—WASF1—conduct disorder	0.00124	0.00135	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—DRD4—conduct disorder	0.00119	0.00129	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—HTR2A—conduct disorder	0.00118	0.00129	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CGA—conduct disorder	0.00118	0.00128	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—HTR2A—conduct disorder	0.00115	0.00126	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—HTR2A—conduct disorder	0.00114	0.00125	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—HTR2A—conduct disorder	0.00112	0.00122	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—HTR2A—conduct disorder	0.00105	0.00115	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—HTR2A—conduct disorder	0.00105	0.00114	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HTR2A—conduct disorder	0.00104	0.00113	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD4—conduct disorder	0.00103	0.00112	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—HTR2A—conduct disorder	0.00102	0.00111	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—WASF1—conduct disorder	0.001	0.00109	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CGA—conduct disorder	0.000983	0.00107	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HTR2A—conduct disorder	0.000954	0.00104	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD4—conduct disorder	0.000946	0.00103	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD4—conduct disorder	0.000939	0.00102	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD4—conduct disorder	0.000932	0.00102	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD4—conduct disorder	0.00092	0.001	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD4—conduct disorder	0.000864	0.000942	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—HTR2A—conduct disorder	0.000852	0.000929	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000846	0.000923	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CGA—conduct disorder	0.000813	0.000887	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—WASF1—conduct disorder	0.000788	0.000859	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HTR2A—conduct disorder	0.000774	0.000844	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD4—conduct disorder	0.000701	0.000764	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—HTR2A—conduct disorder	0.00067	0.00073	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HTR2A—conduct disorder	0.000617	0.000673	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HTR2A—conduct disorder	0.000613	0.000668	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HTR2A—conduct disorder	0.000608	0.000663	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HTR2A—conduct disorder	0.0006	0.000654	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HTR2A—conduct disorder	0.000564	0.000615	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—EP300—conduct disorder	0.000561	0.000612	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD4—conduct disorder	0.000551	0.0006	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—COMT—conduct disorder	0.000531	0.000579	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MAOA—conduct disorder	0.000527	0.000575	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CGA—conduct disorder	0.000501	0.000546	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR2A—conduct disorder	0.000457	0.000498	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—COMT—conduct disorder	0.000367	0.0004	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MAOA—conduct disorder	0.000364	0.000397	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR2A—conduct disorder	0.000359	0.000392	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EP300—conduct disorder	0.000327	0.000357	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EP300—conduct disorder	0.000325	0.000354	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EP300—conduct disorder	0.000318	0.000347	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EP300—conduct disorder	0.000299	0.000326	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EP300—conduct disorder	0.000242	0.000264	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—EP300—conduct disorder	0.000228	0.000248	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—COMT—conduct disorder	0.000226	0.000247	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MAOA—conduct disorder	0.000225	0.000245	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EP300—conduct disorder	0.00019	0.000208	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—EP300—conduct disorder	0.000157	0.000172	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—EP300—conduct disorder	9.7e-05	0.000106	CbGpPWpGaD
